→ The Bill and Melinda Gates Foundation has joined with the UK government to back CARB-X, a public private partnership that aims to support small biotechs developing new vaccines and antibiotics for the growing number of cases of drug resistance. The Gates Foundation is adding $25 million with the British government adding up to $27 million more. CARB-X now has more than $500 million to work with.
→ Sanofi’s new subsidiary Bioverativ has posted some new data demonstrating that its factor VIII therapy for hemophilia A — BIVV001 — extended the half-life of factor VIII to 37 hours.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.Free Subscription